🚨 New study from my research group and All of Us Research Program—270K+ adults—finds that Obesity is linked to a higher risk of 16 diseases.

Class 3 obesity = 11x risk of sleep apnea, 7.7x diabetes, 6.7x fatty liver. 51% of OSA cases may be due to obesity.
evidence.nejm.org/doi/10.1056/...

I’m working on a special podcast project for the obesity scientific community.

Do you have a favorite obesity-related podcast for healthcare and science professionals? Drop your recommendations below—I’d love to check them out.

He’s making little effort to dispel criticism linking him to far-right, neo-Nazi, and modern eugenics ideologies.

Wow, TikTok was a real one till the very end. #tiktokban #blackout

STEP UP Trial Top-lin eResults

Novo Nordisk’s STEP UP trial shows semaglutide 7.2 mg achieved 20.7% weight loss with adherence and 18.7% on average over 72 weeks. 33% of participants lost more than 25% of their weight, outperforming semaglutide 2.4 mg and placebo, with a similar safety profile.

🚨 BREAKING: Zepbound (#Tirzepatide) becomes the first-ever FDA-approved drug for Obstructive Sleep Apnea (OSA)! 🌟
www.fda.gov/news-events/...

BREAKING: Topline results from REDEFINE-1, a Ph3 trial for CagriSema, highlight the novel GLP-1 RA/Amylin RA combo achieving 22.7% weight loss (when paired with diet & exercise) over 68 weeks.

CagriSema demonstrates weight loss efficacy comparable to Tirzepatide.
www.novonordisk.com/news-and-med...

🚨Breaking: Lilly’s Zepbound® (tirzepatide) outperforms Wegovy® (semaglutide) in weight loss trial over 72 weeks

SURMOUNT-5 Top-line results:
🔹 Zepbound: 20.2% avg. weight loss (50.3 lbs)
Vs.
🔹 Wegovy: 13.7% avg. weight loss (33.1 lbs)

🚨 Big News for Oregon! 🚨

Accomplish Health is now LIVE and accepting patients in the Beaver State! 🌟

Don’t wait to start your journey toward better health and confidence. Sign up here: www.accomplish.health/start

When there is substantial evidence that food companies have contributed to the development of obesity—which seems inevitable—could we sue them and force them to subsidize obesity care programs?

The Physiological Cycle of Weight Gain

Progress can sometimes feel slow, but there’s no denying that the narrative around obesity is shifting. More people are paying attention, and the conversation is gaining momentum. While there’s still much work ahead, today, I’m feeling grateful. Wishing you all a joyful Thanksgiving! Gobble gobble.

From interim results of Hall’s group: only minimally processed foods led to fat loss, suggesting that even healthier forms of ultra-processed foods (UPFs) might still be problematic—or at the very least, not conducive to fat loss. What a remarkable finding!

MariTide (maridebart cafraglutide) Phase 2 Top-line Results Over 52 Weeks
🔹HbA1c: -2.2% (paired with -17% total body weight loss in T2D patients)
🔹TBWL: Exceeds 20% (in Obesity with no plateau)

No new safety concerns were observed, and GI side effects showed rapid tachyphylaxis.